Posted by Michael Wonder on 10 Feb 2025
Biodexa receives US FDA fast track designation for eRapa in familial adenomatous polyposis
10 February 2025 - Biodexa Pharmaceuticals announced today that the US FDA has granted fast track designation for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis.
The designation was requested based on the potential for eRapa to address an unmet medical need for familial adenomatous polyposis, a condition which left untreated universally leads to colorectal cancer.
